Health
Hope grows for blood cancer patients, as cell therapy firm’s key trial succeeds – The Times of Israel
Gamida Cell shares surge after results of key trial show flagship drug results in faster blood count recovery, fewer bacterial and viral infections after bone marrow…
Gamida Cell Ltd., a maker of cell and immune therapy technologies, on Wednesday published the results of a key late-stage clinical trial of its flagship drug, which aims to increase the success of bone marrow transplants in blood cancer patients — triggering a surge in its Nasdaq-traded shares.
Gamida’s shares jumped almost 26% on the US exchange Wednesday. The shares have advanced 163% in the past 12 months, leading to a company valuation of $733 million. The firm held its initial public offering…
-
Business19 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News18 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General13 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News15 hours agoTips to improve engagement – Proctor